ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 6, 2021

8:30AM-10:30AM: Abstract Number: 0432

Anti-IL5 Therapy in Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Longitudinal Follow-up Study ≥ 24months

Vasculitis – ANCA-Associated Poster (0414–0436)

8:30AM-10:30AM: Abstract Number: 0345

Anti-MPP-1 Autoantibodies in Systemic Lupus Erythematosus: A Potential Biomarker for Neuropsychiatric Manifestations

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

8:30AM-10:30AM: Abstract Number: 0137

Antiviral Use and Healthcare Resource Utilization Among Patients with Rheumatoid Arthritis and Influenza in Three Influenza Seasons, 2016–2019

Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)

8:30AM-10:30AM: Abstract Number: 0326

Apolipoprotein L1 (APOL1) in African-American SLE: Frequency and Clinical Associations

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

8:30AM-10:30AM: Abstract Number: 0235

Are Comorbidities in Patients with Chronic Inflammatory Rheumatic Diseases Associated with Treatment Adherence to Biosimilars in a Non-medical Switch Scenario?

Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)

8:30AM-10:30AM: Abstract Number: 0038

Arthritis Progression in at Risk Individuals Is Associated with ACPAs Not AMPAs

RA – Etiology & Pathogenesis Poster (0011–0045)

8:30AM-10:30AM: Abstract Number: 0305

Artificial Neural Networks Approaches to Predict Myocardial Fibrosis in Primary Sjögren Syndrome Patients Without Cardiac Symptoms

Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)

8:30AM-10:30AM: Abstract Number: 0172

Assessing Relevant Joints for Monitoring CPPD Diseases: A Systematic Literature Review of Imaging Techniques by the OMERACT Ultrasound – CPPD Subgroup

Imaging of Rheumatic Diseases Poster (0149–0182)

8:30AM-10:30AM: Abstract Number: 0319

Assessment of EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains in Routine Clinical Practice in an Integrated Delivery Network in the United States

Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)

8:30AM-10:30AM: Abstract Number: 0079

Association Between Preconception Complement Levels and Use of Hydroxychloroquine with Pregnancy Outcome in Patients with Primary Antiphospholipid Syndrome and Carriers of Antiphospholipid Antibodies: An International Multicenter Study

Antiphospholipid Syndrome Poster (0069–0083)

8:30AM-10:30AM: Abstract Number: 0334

Association Between Systemic Lupus Erythematosus and Myasthenia Gravis: A Population-Based National Study

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

8:30AM-10:30AM: Abstract Number: 0074

Association of Anti-phospholipid Antibodies (aPL) with Poor Clinical Outcomes in Hospitalized Patients with COVID-19

Antiphospholipid Syndrome Poster (0069–0083)

8:30AM-10:30AM: Abstract Number: 0085

Association of CD20 Inhibitor Use with Severe COVID-19 Outcomes

Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)

8:30AM-10:30AM: Abstract Number: 0082

Association of Current Cigarette Smoking and Obesity with Antiphospholipid Antibodies and Thrombosis in 1216 International Patients Evaluated for Suspected Antiphospholipid Syndrome (APS)

Antiphospholipid Syndrome Poster (0069–0083)

8:30AM-10:30AM: Abstract Number: 0077

Association of Lupus Nephritis and Other Clinical Features with Antiphospholipid Antibody Positivity Among Patients with Systemic Lupus Erythematosus

Antiphospholipid Syndrome Poster (0069–0083)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].